MannKind Corp
MNKD4.950USD
-0.089-1.79%
Fechamento 05/01, 16:00（ET）Cotações atrasadas em 15 min
1.50BValor de mercado
54.36P/L TTM
Mais detalhes de MannKind Corp Empresa
MannKind Corporation is focused on the development and commercialization of inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The Company's technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices. In its endocrine business unit, it commercializes two products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its pipeline products include Pediatric Afrezza (insulin human) Inhalation Powder, MNKD-101 and MNKD-201.
Informações da empresa
Código da empresaMNKD
Nome da EmpresaMannKind Corp
Data de listagemJul 28, 2004
Fundado em1991
CEODr. Michael E. Castagna, Pharm.D.
Número de funcionários407
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 28
Endereço1 Casper Street
CidadeDANBURY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal06810
Telefone18186615000
Sitehttps://mannkindcorp.com/
Código da empresaMNKD
Data de listagemJul 28, 2004
Fundado em1991
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Mr. Ronald J. Consiglio
Mr. Ronald J. Consiglio
Independent Director
Independent Director
118.43K
--
Ms. Jennifer Grancio
Ms. Jennifer Grancio
Independent Director
Independent Director
110.70K
--
Dr. Sabrina Kay
Dr. Sabrina Kay
Independent Director
Independent Director
107.03K
--
Ms. Lauren M. Sabella
Ms. Lauren M. Sabella
Executive Vice President - Operations
Executive Vice President - Operations
106.41K
-45.01%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael E. Castagna, Pharm.D.
Dr. Michael E. Castagna, Pharm.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.47M
-2.62%
Mr. Steven B. Binder
Mr. Steven B. Binder
Director
Director
696.53K
-9.51%
Dr. David B. Thomson, J.D., Ph.D.
Dr. David B. Thomson, J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
609.34K
+16.18%
Mr. Dominic (Nick) Marasco
Mr. Dominic (Nick) Marasco
President, Endocrine Business Unit
President, Endocrine Business Unit
252.00K
--
Dr. Burkhard Blank, M.D.
Dr. Burkhard Blank, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
194.25K
-28.25%
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Director
Independent Director
176.15K
--
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Por RegiãoUSD
Nome
Receita
Proporção
United States
285.50M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product sales
178.56M
62.54%
Royalties
102.33M
35.84%
Services
4.61M
1.62%
Acionista
Tempo de atualização: dom, 23 de fev
Tempo de atualização: dom, 23 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Estatísticas dos acionistas
Acionista
Proporção
BlackRock Institutional Trust Company, N.A.
6.98%
The Vanguard Group, Inc.
5.26%
State Street Global Advisors (US)
3.27%
Avoro Capital Advisors LLC
2.88%
Nitorum Capital, L.P.
2.88%
Other
78.72%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
24.45%
Investment Advisor
16.58%
Hedge Fund
10.78%
Research Firm
3.38%
Individual Investor
1.63%
Pension Fund
0.35%
Bank and Trust
0.33%
Venture Capital
0.02%
Other
42.48%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
464
175.74M
57.84%
+7.73M
2024Q4
470
175.08M
57.68%
+5.91M
2024Q3
459
161.03M
58.24%
+6.62M
2024Q2
442
145.29M
52.88%
-4.76M
2024Q1
433
140.98M
52.03%
-8.31M
2023Q4
422
141.98M
52.59%
-12.51M
2023Q3
418
148.17M
55.00%
-3.06M
2023Q2
412
143.59M
53.56%
-12.28M
2023Q1
412
147.80M
55.93%
-4.58M
2022Q4
408
144.92M
55.01%
+311.67K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
21.21M
6.98%
+360.93K
+1.73%
Dec 31, 2024
The Vanguard Group, Inc.
16.00M
5.26%
+420.33K
+2.70%
Dec 31, 2024
State Street Global Advisors (US)
9.95M
3.27%
+350.64K
+3.65%
Dec 31, 2024
Avoro Capital Advisors LLC
8.75M
2.88%
--
--
Dec 31, 2024
Nitorum Capital, L.P.
8.75M
2.88%
-410.19K
-4.48%
Dec 31, 2024
Geode Capital Management, L.L.C.
6.37M
2.1%
+35.35K
+0.56%
Dec 31, 2024
Two Sigma Investments, LP
6.27M
2.06%
+579.24K
+10.18%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.89M
1.61%
+3.59M
+275.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.48M
1.47%
+49.96K
+1.13%
Dec 31, 2024
D. E. Shaw & Co., L.P.
4.27M
1.41%
+798.47K
+23.01%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Invesco Biotechnology & Genome ETF
2.16%
ALPS Medical Breakthroughs ETF
1.21%
VictoryShares Small Cap Free Cash Flow ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.54%
First Trust Small Cap Growth AlphaDEX Fund
0.41%
Invesco NASDAQ Future Gen 200 ETF
0.4%
Global X Aging Population ETF
0.32%
iShares Micro-Cap ETF
0.29%
SPDR S&P Biotech ETF
0.28%
First Trust Small Cap Core Alphadex Fund
0.22%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção2.16%
ALPS Medical Breakthroughs ETF
Proporção1.21%
VictoryShares Small Cap Free Cash Flow ETF
Proporção0.61%
Federated Hermes MDT Small Cap Core ETF
Proporção0.54%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.41%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.4%
Global X Aging Population ETF
Proporção0.32%
iShares Micro-Cap ETF
Proporção0.29%
SPDR S&P Biotech ETF
Proporção0.28%
First Trust Small Cap Core Alphadex Fund
Proporção0.22%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados